Biomarkers /
C11orf30
Overview
C11orf30 is altered in 0.53% of all cancers with lung adenocarcinoma, cutaneous melanoma, high grade ovarian serous adenocarcinoma, bladder urothelial carcinoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations [3].
The most common alterations in C11orf30 are C11orf30 Mutation (2.22%), C11orf30 R744S (0.13%), C11orf30 T150M (0.16%), C11orf30 I494V (0.16%), and C11orf30 P439S (0.28%) [3].
Clinical Trials
Significance of C11orf30 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.